Literature DB >> 31534203

Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study.

Serdar Altinay1, Laurent Arnould2, Noella Bletard3, Cecile Colpaert4, Franceska Dedeurwaerdere5, Benjamin Dessauvagie6, Valérie Duwel7, Giuseppe Floris8,9, Stephen Fox10, Clara Gerosa11, Shabnam Jaffer12, Eline Kurpershoek13, Magali Lacroix-Triki14, Andoni Laka15, Kathleen Lambein16, Gaëtan Marie MacGrogan17, Caterina Marchió18,19, Dolores Martin Martinez20, Sharon Nofech-Mozes21, Dieter Peeters22,23, Alberto Ravarino11, Emily Reisenbichler24, Erika Resetkova25, Souzan Sanati26, Anne-Marie Schelfhout27, Vera Schelfhout22, Abeer M Shaaban28, Renata Sinke13, Claudia Maria Stanciu-Pop29, Claudia Stobbe13, Carolien H M van Deurzen30, Koen Van de Vijver31, Anne-Sophie Van Rompuy8, Stephanie Verschuere5, Anne Vincent-Salomon32, Hannah Wen33, Hélène Dano34, Caroline Bouzin35, Christine Galant34,36, Mieke R Van Bockstal37,38.   

Abstract

Histopathological assessment of ductal carcinoma in situ, a nonobligate precursor of invasive breast cancer, is characterized by considerable interobserver variability. Previously, post hoc dichotomization of multicategorical variables was used to determine the "ideal" cutoffs for dichotomous assessment. The present international multicenter study evaluated interobserver variability among 39 pathologists who performed upfront dichotomous evaluation of 149 consecutive ductal carcinomas in situ. All pathologists independently assessed nuclear atypia, necrosis, solid ductal carcinoma in situ architecture, calcifications, stromal architecture, and lobular cancerization in one digital slide per lesion. Stromal inflammation was assessed semiquantitatively. Tumor-infiltrating lymphocytes were quantified as percentages and dichotomously assessed with a cutoff at 50%. Krippendorff's alpha (KA), Cohen's kappa and intraclass correlation coefficient were calculated for the appropriate variables. Lobular cancerization (KA = 0.396), nuclear atypia (KA = 0.422), and stromal architecture (KA = 0.450) showed the highest interobserver variability. Stromal inflammation (KA = 0.564), dichotomously assessed tumor-infiltrating lymphocytes (KA = 0.520), and comedonecrosis (KA = 0.539) showed slightly lower interobserver disagreement. Solid ductal carcinoma in situ architecture (KA = 0.602) and calcifications (KA = 0.676) presented with the lowest interobserver variability. Semiquantitative assessment of stromal inflammation resulted in a slightly higher interobserver concordance than upfront dichotomous tumor-infiltrating lymphocytes assessment (KA = 0.564 versus KA = 0.520). High stromal inflammation corresponded best with dichotomously assessed tumor-infiltrating lymphocytes when the cutoff was set at 10% (kappa = 0.881). Nevertheless, a post hoc tumor-infiltrating lymphocytes cutoff set at 20% resulted in the highest interobserver agreement (KA = 0.669). Despite upfront dichotomous evaluation, the interobserver variability remains considerable and is at most acceptable, although it varies among the different histopathological features. Future studies should investigate its impact on ductal carcinoma in situ prognostication. Forthcoming machine learning algorithms may be useful to tackle this substantial diagnostic challenge.

Entities:  

Mesh:

Year:  2019        PMID: 31534203      PMCID: PMC7983551          DOI: 10.1038/s41379-019-0367-9

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  44 in total

1.  Consistency in the observation of features used to classify duct carcinoma in situ (DCIS) of the breast.

Authors:  A G Douglas-Jones; J M Morgan; M A Appleton; R L Attanoos; A Caslin; C S Champ; M Cotter; N S Dallimore; A Dawson; R W Fortt; A P Griffiths; M Hughes; P A Kitching; C O'Brien; A M Rashid; D Stock; A Verghese; D W Williams; N W Williams; S Williams
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

2.  Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria.

Authors:  S J Schnitt; J L Connolly; F A Tavassoli; R E Fechner; R L Kempson; R Gelman; D L Page
Journal:  Am J Surg Pathol       Date:  1992-12       Impact factor: 6.394

3.  Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. European Commission Working Group on Breast Screening Pathology.

Authors:  J P Sloane; I Amendoeira; N Apostolikas; J P Bellocq; S Bianchi; W Boecker; G Bussolati; D Coleman; C E Connolly; P Dervan; V Eusebi; C De Miguel; M Drijkoningen; C W Elston; D Faverley; A Gad; J Jacquemier; M Lacerda; J Martinez-Penuela; C Munt; J L Peterse; F Rank; M Sylvan; V Tsakraklides; B Zafrani
Journal:  Hum Pathol       Date:  1998-10       Impact factor: 3.466

4.  Whole slide imaging equivalency and efficiency study: experience at a large academic center.

Authors:  Matthew G Hanna; Victor E Reuter; Meera R Hameed; Lee K Tan; Sarah Chiang; Carlie Sigel; Travis Hollmann; Dilip Giri; Jennifer Samboy; Carlos Moradel; Andrea Rosado; John R Otilano; Christine England; Lorraine Corsale; Evangelos Stamelos; Yukako Yagi; Peter J Schüffler; Thomas Fuchs; David S Klimstra; S Joseph Sirintrapun
Journal:  Mod Pathol       Date:  2019-02-18       Impact factor: 7.842

5.  Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012.

Authors:  M C van Maaren; M Lagendijk; M M A Tilanus-Linthorst; L de Munck; R M Pijnappel; M K Schmidt; J Wesseling; L B Koppert; S Siesling
Journal:  Eur J Cancer       Date:  2018-07-28       Impact factor: 9.162

Review 6.  Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review.

Authors:  M Toss; I Miligy; A M Thompson; H Khout; A R Green; I O Ellis; E A Rakha
Journal:  Breast       Date:  2017-07-22       Impact factor: 4.380

7.  Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast.

Authors:  P Bethwaite; N Smith; B Delahunt; D Kenwright
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

8.  Carcinoma in situ of the breast in New South Wales, Australia: Current status and trends over the last 40 year.

Authors:  Gemma Jacklyn; Stephen Morrell; Kevin McGeechan; Nehmat Houssami; Les Irwig; Nirmala Pathmanathan; Alexandra Barratt
Journal:  Breast       Date:  2017-09-05       Impact factor: 4.380

9.  Trends in breast cancer mortality by stage at diagnosis among young women in the United States.

Authors:  Fangjian Guo; Yong-Fang Kuo; Ya Chen Tina Shih; Sharon H Giordano; Abbey B Berenson
Journal:  Cancer       Date:  2018-09-06       Impact factor: 6.860

Review 10.  Current approach and future perspective for ductal carcinoma in situ of the breast.

Authors:  Chizuko Kanbayashi; Hiroji Iwata
Journal:  Jpn J Clin Oncol       Date:  2017-08-01       Impact factor: 3.019

View more
  10 in total

1.  Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast.

Authors:  Claudia Stanciu-Pop; Marie-Cécile Nollevaux; Martine Berlière; Francois P Duhoux; Latifa Fellah; Christine Galant; Mieke R Van Bockstal
Journal:  Virchows Arch       Date:  2021-01-27       Impact factor: 4.064

2.  Infiltration pattern predicts metastasis and progression better than the T-stage and grade in pancreatic neuroendocrine tumors: a proposal for a novel infiltration-based morphologic grading.

Authors:  Orhun Cig Taskin; Michelle D Reid; Pelin Bagci; Serdar Balci; Ayse Armutlu; Deniz Demirtas; Burcin Pehlivanoglu; Burcu Saka; Bahar Memis; Emine Bozkurtlar; Can Berk Leblebici; Adelina Birceanu; Yue Xue; Mert Erkan; Yersu Kapran; Arzu Baygul; Cenk Sokmensuer; Aldo Scarpa; Claudio Luchini; Olca Basturk; Volkan Adsay
Journal:  Mod Pathol       Date:  2021-12-30       Impact factor: 7.842

3.  Pilot study to evaluate tools to collect pathologist annotations for validating machine learning algorithms.

Authors:  Katherine Elfer; Sarah Dudgeon; Victor Garcia; Kim Blenman; Evangelos Hytopoulos; Si Wen; Xiaoxian Li; Amy Ly; Bruce Werness; Manasi S Sheth; Mohamed Amgad; Rajarsi Gupta; Joel Saltz; Matthew G Hanna; Anna Ehinger; Dieter Peeters; Roberto Salgado; Brandon D Gallas
Journal:  J Med Imaging (Bellingham)       Date:  2022-07-27

4.  Digital Image Analysis for Estimating Stromal CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma.

Authors:  Iny Jhun; Daniel Shepherd; Yin P Hung; Emilio Madrigal; Long P Le; Mari Mino-Kenudson
Journal:  J Pathol Inform       Date:  2021-07-05

Review 5.  The Diagnosis of Hyalinizing Trabecular Tumor: A Difficult and Controversial Thyroid Entity.

Authors:  Esther Diana Rossi; Mauro Papotti; William Faquin; Luigi Maria Larocca; Liron Pantanowitz
Journal:  Head Neck Pathol       Date:  2019-09-30

Review 6.  Preneoplastic Low-Risk Mammary Ductal Lesions (Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ Spectrum): Current Status and Future Directions.

Authors:  Thaer Khoury
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

7.  Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast.

Authors:  Marie Colombe Agahozo; Mieke van Bockstal; Pieter J Westenend; Christine Galant; Kathleen Lambein; Emily Reisenbichler; Renata Sinke; Serena Wong; Carolien H M van Deurzen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-01-25       Impact factor: 2.673

8.  Grading variation in 2,934 patients with ductal carcinoma in situ of the breast: the effect of laboratory- and pathologist-specific feedback reports.

Authors:  Carmen van Dooijeweert; Paul J van Diest; Inge O Baas; Elsken van der Wall; Ivette A G Deckers
Journal:  Diagn Pathol       Date:  2020-05-11       Impact factor: 2.644

9.  Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.

Authors:  Emma J Groen; Jan Hudecek; Lennart Mulder; Maartje van Seijen; Mathilde M Almekinders; Stoyan Alexov; Anikó Kovács; Ales Ryska; Zsuzsanna Varga; Francisco-Javier Andreu Navarro; Simonetta Bianchi; Willem Vreuls; Eva Balslev; Max V Boot; Janina Kulka; Ewa Chmielik; Ellis Barbé; Mathilda J de Rooij; Winand Vos; Andrea Farkas; Natalja E Leeuwis-Fedorovich; Peter Regitnig; Pieter J Westenend; Loes F S Kooreman; Cecily Quinn; Giuseppe Floris; Gábor Cserni; Paul J van Diest; Esther H Lips; Michael Schaapveld; Jelle Wesseling
Journal:  Breast Cancer Res Treat       Date:  2020-07-30       Impact factor: 4.872

10.  Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.

Authors:  Serdar Altinay; Laurent Arnould; Maschenka Balkenhol; Glenn Broeckx; Octavio Burguès; Cecile Colpaert; Franceska Dedeurwaerdere; Benjamin Dessauvagie; Valérie Duwel; Giuseppe Floris; Stephen Fox; Clara Gerosa; Delfyne Hastir; Shabnam Jaffer; Eline Kurpershoek; Magali Lacroix-Triki; Andoni Laka; Kathleen Lambein; Gaëtan Marie MacGrogan; Caterina Marchiò; Maria-Dolores Martin Martinez; Sharon Nofech-Mozes; Dieter Peeters; Alberto Ravarino; Emily Reisenbichler; Erika Resetkova; Souzan Sanati; Anne-Marie Schelfhout; Vera Schelfhout; Abeer Shaaban; Renata Sinke; Claudia M Stanciu-Pop; Carolien H M van Deurzen; Koen K Van de Vijver; Anne-Sophie Van Rompuy; Anne Vincent-Salomon; Hannah Y Wen; Serena Wong; Mieke R Van Bockstal; Aline François; Caroline Bouzin; Christine Galant
Journal:  Mod Pathol       Date:  2021-07-03       Impact factor: 7.842

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.